After that therapy con cellule Car-T it has revolutionized the treatment of many blood tumorsit’s time to the study a new generation cell therapysimilar but more sensitivewhich is capable of hitting i too solid tumors: call Hit (Hla-independent T cell)in the first tests laboratory on mice And managed to eradicate completely i tumors Of rene, pancreas e ovary. The result, which after the road to future clinical trials on humansAnd published in the journal Science by researchers at the Columbia Initiative in Cell Engineering and Therapy (Cicet) in New York.
The team is led by Michel Sadelain, one of the pioneers of current Car-T therapies, which are based on the use of particular cells of the immune system (T lymphocytes) genetically modified in the laboratory to recognize and attack specific tumor cells. Those in the blood are usually easy to detect because they are covered with numerous CD19 molecules that act as targets. Things get more complicated in solid tumorsbecause theirs cells they are more MIXED e until now it was thought that they did not share a common target molecule. Cicet researchers but they discovered that some types of solid tumors have one thing in common moleculeil CD70which could serve as target. All their cells express it, but some do so at very low levels and for this reason they had not been identified until now.
If conventional CAR-T cells can only detect tumor cells that express many target molecules, the new Hit cells developed in Sadelain’s laboratory result much more sensitive and for this reason they manage to detect Also tumor cells who have a small number of target molecules. In experiments on laboratory mice, Hit cells programmed to target CD70 have completely eradicated pancreatic, kidney and ovarian tumors, sparing healthy cells which do not express CD70.
Encouraged by these early results, the researchers are planning to test Hit CD70 cells on some patients at Columbia University Irving Medical Center. The new cell therapy could prove useful in at least 20 other forms of cancerincluding the glioblastoma el’pancreatic adenocarcinoma.
Reproduction reserved © Copyright ANSA
